TCT 2025: STORM-PE Trial Demonstrates Safety and Efficacy of Mechanical Thrombectomy in Intermediate-High-Risk Pulmonary Embolism
The STORM-PE randomized controlled trial, presented at TCT 2025 in San Francisco, USA, demonstrated the efficacy of mechanical thrombectomy.
Computer-assisted vacuum thrombectomy combined with anticoagulation (CAVT) achieved a significantly greater improvement in right ventricular function compared with anticoagulation (AC) alone in patients with acute intermediate-high risk pulmonary embolism (PE).
Dr. Robert Lookstein of Mount Sinai Health System presented the findings, marking the first randomized trial in over a decade to compare mechanical thrombectomy with standard anticoagulation for acute PE.
Author's summary: TCT 2025 presents STORM-PE trial results.
More News
- Orchestra BioMed, Terumo terminate drug-eluting balloon distro deal in $30M agreement
- Mason, Long-Time Poultry Judging Coach, Remembered for Career Devoted to Education
- Gates Champions Human Welfare Over Climate Alarmism Narrative
- Leonard Green acquires Epiphany Dermatology from CI | PE Hub
- Mexico’s poultry output continues steady growth
- NGP-backed Cygnet Energy to buy Kiwetinohk Energy for $1bn | PE Hub
- New president of The Church of Jesus Christ of Latter-day Saints inherits a global faith far more diverse than many realize – Baptist News Global
- Materialise drives personalised surgery from niche to norm
- Art the Clown Owes One of His 'Terrifier' Victims a Lot of Money
- Banging bumper fun from 2000AD!